Literature DB >> 21169532

The effect of graded cyclic stretching on extracellular matrix-related gene expression profiles in cultured primary human lamina cribrosa cells.

Barry Quill1, Neil G Docherty, Abbot F Clark, Colm J O'Brien.   

Abstract

PURPOSE: Cyclic stretching of the glial fibrillary acidic protein (GFAP)-negative lamina cribrosa (LC) cell in vitro is associated with transcriptomic changes in genes involved in extracellular matrix (ECM) dynamics in vivo, thereby implicating this cell type in the pathophysiologic changes of the optic nerve head (ONH) in glaucoma. The purpose of the study was to determine whether exposure to different grades of mechanical stretch progressively alters the expression of ECM genes in cultured LC cells.
METHODS: Primary cultures of human LC cells from three separate donors were maintained in static culture or exposed to low-level strain (3% ± 0.5% elongation, 1 Hz) for 24 hours. A baseline comparison of the expression of 62 genes involved in ECM dynamics was performed with low-density gene arrays (LDAs). The 3% protocol was used in a 24-hour period of baseline dynamic low-level stretch, and gene expression was compared with that occurring in a further 24-hour exposure to a 12.5% or a 20% stretch. Gene expression levels were determined by qRT-PCR.
RESULTS: LC cells displayed a nonlinear, transcriptional response to the mechanical stretch. Ten ECM-related and growth factor genes were altered by 3% strain versus static culture (nine downregulated and one upregulated). Increasing strain from 3% to 20% resulted in a significant increase in expression of 15 ECM-elated genes. Only one gene (epidermal growth factor) was increased between the 3% and 12.5% strains.
CONCLUSIONS: Low-level, pulsatile, cyclic strain resets a lower baseline expression of several glaucoma-associated ECM genes. The LC ECM gene response occurs above a fourfold increase in baseline strain (12.5% strain) in vitro. The study supports the use of a nonstatic baseline when studying the effect of stretch (or strain) on the activation of ONH-derived, ECM-producing cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21169532     DOI: 10.1167/iovs.10-5467

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  7 in total

1.  Proteomics analyses of human optic nerve head astrocytes following biomechanical strain.

Authors:  Ronan S Rogers; Moyez Dharsee; Suzanne Ackloo; Jeremy M Sivak; John G Flanagan
Journal:  Mol Cell Proteomics       Date:  2011-11-29       Impact factor: 5.911

2.  Isolation and characterization of human optic nerve head astrocytes and lamina cribrosa cells.

Authors:  Navita N Lopez; Abbot F Clark; Tara Tovar-Vidales
Journal:  Exp Eye Res       Date:  2020-06-06       Impact factor: 3.467

3.  Eye-specific IOP-induced displacements and deformations of human lamina cribrosa.

Authors:  Ian A Sigal; Jonathan L Grimm; Ning-Jiun Jan; Korey Reid; Don S Minckler; Donald J Brown
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-01-02       Impact factor: 4.799

4.  Dynamic testing of regional viscoelastic behavior of canine sclera.

Authors:  Joel R Palko; Xueliang Pan; Jun Liu
Journal:  Exp Eye Res       Date:  2011-10-05       Impact factor: 3.467

5.  Biomechanics of the optic nerve head and peripapillary sclera in a mouse model of glaucoma.

Authors:  Arina Korneva; Elizabeth C Kimball; Joan L Jefferys; Harry A Quigley; Thao D Nguyen
Journal:  J R Soc Interface       Date:  2020-12-16       Impact factor: 4.118

Review 6.  Life under pressure: The role of ocular cribriform cells in preventing glaucoma.

Authors:  Jayter S Paula; Colm O'Brien; W Daniel Stamer
Journal:  Exp Eye Res       Date:  2016-08-25       Impact factor: 3.467

7.  Matrix Mechanotransduction via Yes-Associated Protein in Human Lamina Cribrosa Cells in Glaucoma.

Authors:  Rory Murphy; Mustapha Irnaten; Alan Hopkins; Jeffrey O'Callaghan; W Daniel Stamer; Abbot F Clark; Deborah Wallace; Colm J O'Brien
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-01-03       Impact factor: 4.799

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.